Literature DB >> 21971004

Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.

Makoto Naoi1, Wakako Maruyama, Keiko Inaba-Hasegawa, Yukihiro Akao.   

Abstract

In Parkinson's disease, type B monoamine oxidase (MAO-B) is proposed to play an important role in the pathogenesis through production of reactive oxygen species and neurotoxins from protoxicants, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. In addition, inhibitors of MAO-B protect neurons in the cellular and animal models of Parkinson's and Alzheimer's diseases. However, the role of type A MAO (MAO-A) in neuronal death and neuroprotection by MAO-B inhibitors has been scarcely elucidated. This chapter presents our recent results on the involvement of MAO-A in the activation of mitochondrial death signal pathway and in the induction of prosurvival genes to prevent cell death with MAO-B inhibitors. The roles of MAO-A in the regulation of neuronal survival and death are discussed in concern to find a novel strategy to protect neurons in age-associated neurodegenerative disorders and depression.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21971004     DOI: 10.1016/B978-0-12-386467-3.00005-4

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  7 in total

1.  Aspartic acid substitutions in monoamine oxidase-A reveal both catalytic-dependent and -independent influences on cell viability and proliferation.

Authors:  Zelan Wei; Tamara Satram-Maharaj; Bradley Chaharyn; Kelly Kuski; Paul R Pennington; Xia Cao; Jennifer Chlan; Darrell D Mousseau
Journal:  J Neural Transm (Vienna)       Date:  2012-03-03       Impact factor: 3.575

Review 2.  Kinetics, mechanism, and inhibition of monoamine oxidase.

Authors:  Rona R Ramsay; Alen Albreht
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

Review 3.  Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.

Authors:  Makoto Naoi; Peter Riederer; Wakako Maruyama
Journal:  J Neural Transm (Vienna)       Date:  2015-01-22       Impact factor: 3.575

4.  Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.

Authors:  Keiko Inaba-Hasegawa; Yukihiro Akao; Wakako Maruyama; Makoto Naoi
Journal:  J Neural Transm (Vienna)       Date:  2012-09-12       Impact factor: 3.575

5.  Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria.

Authors:  Makoto Naoi; Wakako Maruyama; Hong Yi
Journal:  J Neural Transm (Vienna)       Date:  2013-05-17       Impact factor: 3.575

6.  Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection.

Authors:  Miroslava Cuperlovic-Culf; Emma L Cunningham; Hossen Teimoorinia; Anuradha Surendra; Xiaobei Pan; Steffany A L Bennett; Mijin Jung; Bernadette McGuiness; Anthony Peter Passmore; David Beverland; Brian D Green
Journal:  Sci Rep       Date:  2021-05-20       Impact factor: 4.996

7.  MicroRNA-142 reduces monoamine oxidase A expression and activity in neuronal cells by downregulating SIRT1.

Authors:  Amrita Datta Chaudhuri; Sowmya V Yelamanchili; Howard S Fox
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.